Chapter 5 of 25
- Symptoms? Arrange diagnostic assessment
- No symptoms? Check history and risk
- Use the appropriate validated screening test
- Follow the result-specific pathway
What you will learn
Compare screening methods; understand differences between guideline systems; know when routine schedules do not apply.
What each test measures
Primary HPV testing detects cancer-associated viral material and can identify risk before cell changes are visible. A Pap test, or cervical cytology, examines cells for abnormalities. Cotesting combines HPV testing and cytology. Visual inspection with acetic acid, or VIA, looks for changes after dilute acetic acid is applied by a trained provider; it is used in some resource-adapted programmes. A positive screen is not a cancer diagnosis.
Clinician collection usually uses a speculum and a small brush. Tell the team about pregnancy, discomfort, menopause, previous trauma or difficulty with examinations. Self-collection uses a vaginal sample for an authorized HPV assay; it is not a self-performed Pap test. The device, assay, setting and follow-up pathway must be validated locally. A positive self-collected result may require clinician sampling or colposcopy.
Guideline comparison for asymptomatic average-risk people
| System | Starting age and typical interval | Important context |
|---|---|---|
| WHO programme guidance | HPV DNA from 30, generally every 5–10 years | HIV: begin at 25, generally every 3–5 years, with a dedicated pathway |
| India national operational framework | VIA ages 30–65, every 5 years | Describes a public-health programme; local HPV-based services may differ |
| ACS, December 2025 | From 25 to at least 65; clinician HPV every 5 years preferred | Approved self-collected HPV every 3 years; cotest every 5 or Pap every 3 are alternatives |
| USPSTF final 2018 guidance retrieved | Ages 21–29 Pap every 3 years; 30–65 Pap every 3, HPV every 5 or cotest every 5 | The retrieved December 2024 update remains labelled draft |
| HRSA/WPSI final January 2026 | Ages 21–29 Pap every 3; 30–65 HPV every 5 preferred, or cotest every 5 | Pap every 3 if HPV unavailable; approved self-collection offered at 30–65 |
These are programme summaries, not instructions to choose the longest interval. Guidelines weigh benefits, false positives, available tests and system capacity differently. Use one locally appropriate pathway with your clinician instead of mixing starting ages from one system with follow-up rules from another.
Who needs a different pathway?
Prior CIN2, CIN3, AIS, cervical cancer, an unresolved abnormal result, HIV, transplantation or other immune suppression can require closer or longer surveillance. A vaccinated person still follows screening guidance. Someone with symptoms needs diagnostic assessment rather than waiting for the next screening invitation. Pregnancy may change procedures and timing but does not make abnormal results irrelevant.
After a total hysterectomy for benign disease, routine cervical screening is often unnecessary if the cervix was removed and there is no relevant high-grade history. If the cervix remains, screening continues. Confirm the operation and pathology rather than guessing from a scar or the word “hysterectomy.”
Stopping safely
Age 65 is not an automatic stop. Adequate documented negative prior tests and absence of high-risk history are essential. If history is unknown or screening has been irregular, further testing may be appropriate. People treated for high-grade precancer may need surveillance for at least 25 years under US risk-based guidance, including beyond 65. Local protocols differ.
Misconception and common question
“Screen every year to be safest” is not generally correct for average risk: excessive testing can lead to avoidable procedures. Does a normal test explain new bleeding? No. Arrange an examination; screening does not rule out every cause of symptoms.
Take-home messages
Know your test, result and next action. Ensure positive screens receive follow-up. Use the screening education tool to prepare a discussion, never to generate an individualized order.
References and review status
- WHO — Screening and treatment recommendations, 2021
- India national operational framework: management of common cancers
- American Cancer Society — Cervical screening guideline (December 2025 update)
- USPSTF — Cervical cancer screening: final recommendation retrieved (2018)
- HRSA/WPSI — Final Women's Preventive Services Guidelines, 5 January 2026
- ASCCP — Risk-based management consensus guidelines and resources
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy